Q-omics provides the consensus-scored PGA5 profile across patient tissues and cancer cell-line models. PGA5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PGA5 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PGA5 RNA expression shows 13,465 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where PGA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PGA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PGA5 survival associations across molecular data types. PGA5 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PGA5 RNA expression–survival associations across cancer types. High PGA5 expression shows unfavorable associations in KICH, LUSC, LIHC, BLCA and UCEC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PGA5 RNA expression.
This table summarizes PGA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PGA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PGA5 shows lower tumor expression in THCA, KICH, UCEC, BRCA and COAD and higher tumor expression in KIRC. The KIRC box plot shows higher PGA5 RNA expression in tumor versus normal tissue (log2 FC = +1.050, t-test p < 0.001).
This table shows molecular features associated with PGA5 in patient tissues and cancer cell lines. In patient samples, PGA5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PGA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE.
